Heparin is the standard anticoagulant for patients undergoing cardiopulmonary bypass. There are some patients for whom heparin is unsuitable and ancrod (a defibrinogenating enzyme) has been used as an alternative. We present a patient with heparin-induced thrombocytopenia in whom treatment ancrod was ineffective. The addition of danaparoid sodium (a heparinoid) allowed safe cardiopulmonary bypass. We discuss the reasons for this and suggest that the combination of ancrod and danaparoid sodium is a logical one in such cases.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0003-4975(98)00511-6 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!